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Abstract
Background: Abnormal amplification/expression of HER-2/neu oncogene has been causally linked
with tumorigenesis and metastasis in breast cancer and associated with shortened overall survival
of patients. Recently, heat shock protein 27 (Hsp27) was reported to be highly expressed in HER-
2/neu positive tumors and cell lines. However, putative functional links between phosphorylation
of Hsp27 with HER-2/neu status and other clinicopathological features remain to be elucidated.
Results:  Comparative phosphoproteomic studies of HER-2/neu  positive and -negative breast
tumors revealed that Hsp27, one of the identified phosphoproteins, was highly phosphorylated in
HER-2/neu positive tumors. The extent of Hsp27 phosphorylation at its Ser15, Ser78 and Ser82
residues were further evaluated with site-specific antibodies in tumor samples by tissue lysate
array- and tissue microarray-based analyses, and in the BT474 breast cancer cell line treated with
heregulin α1 (HRG α1) or the p38 MAPK inhibitor, SB203580. The tissue lysate array study
indicated that only the level of pSer78 in HER-2/neu positive tumors was more than 2-fold that in
HER-2/neu negative tumors. Treatment of BT474 cells with HRG α1 and SB203580 indicated that
Ser78  phosphorylation was mainly regulated by the HER-2/neu-p38 MAPK pathway.
Immunohistochemical staining of sections from a tissue microarray with 97 breast tumors showed
that positive staining of pSer78 significantly correlated with HER-2/neu (p = 0.004) and lymph node
positivity (p = 0.026).
Conclusion:  This investigation demonstrated the significant correlation of enhanced
phosphorylation of the Ser78 residue of Hsp27 with HER-2/neu and lymph node positivity in breast
cancer.
Background
Heat shock proteins (Hsp's) are a large and heterogeneous
group of chaperones that include the high-molecular-
weight (HMW) Hsp's, such as Hsp70 and Hsp90, and the
low-molecular-weight (LMW) Hsp's, including Hsp27
and α-B-crystallin. Hsp synthesis can be induced by both
physiological and pathological conditions, such as heat
shock, oxidative stress, mitogenic signals, inflammation,
infection and neoplastic transformation [1,2]. The HMW
Hsp's are involved in protein folding, oligomerization
and translocation [3], whereas the LMW Hsp's are related
to actin dynamics [4] and to inhibition of apoptosis by
interacting with the cytochrome c/Apaf-1/dATP complex
in the procaspase-9 pathway or preventing Daxx protein
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association with Fas and Ask1 [5]. Hsp27 has been found
to be overexpressed in breast [6], prostate [7], gastric [8],
ovarian [9] and urinary bladder [10] cancers, and its over-
expression is associated with aggressive tumor behavior
and poor survival rate [11] and adverse resistance to
chemotherapy [12]. Hsp27 was also found in the serum of
patients with breast cancer and proposed as a possible
diagnostic marker for breast cancer [13].
Hsp27 activity is regulated by post-translational modifica-
tions such as phosphorylation [3]. Phosphorylation of
Hsp27 is catalyzed by MAPKAPK-2 and MAPKAPK-3 [14],
protein kinase C (PKC) [15], protein kinase D [16], and
cGMP-dependent protein kinase [17]. Endoplasmic retic-
ulum stress induces the phosphorylation of Hsp27 [18]
and Stat 3 modulates Hsp27 expression and facilitates
phosphorylation at Ser78  [19]. Phosphorylation at its
three serine residues (Ser15, Ser78 and Ser82) induces redis-
tribution of the large oligomers into small tetrameric units
[20]. In addition, phosphorylation of Hsp27 results in its
translocation from the cytosol to the nucleus and prevents
apoptosis [21]. Recently, Shin et al [22] found that block-
ing the phosphorylation of Hsp27 by the specific inhibi-
tor KRIBB3 inhibits tumor cell migration and invasion. In
clinical cancer tissues, including renal cell carcinoma [23]
and hepatocellular carcinoma [24] and other tissues [25],
various phosphorylation patterns of Hsp27 have been
found to associate with the aggressiveness of tumor phe-
notype. For example, attenuated phosphorylation of
Hsp27 correlated with tumor progression in hepatocellu-
lar carcinoma [24], whereas in renal cell carcinoma,
Hsp27 phosphorylation was enhanced, as compared to
non-tumor samples [26] and Ser82 was found to be more
highly phosphorylated than Ser15 [23]. These apparently
paradoxical observations may indicate that phosphoryla-
tion of Hsp27 may occur in a tissue- and/or tumor-
dependent manner.
In this study, we combined the use of laser capture micro-
scopy (LCM), gel-based proteomics and the phosphosen-
sor dye (Pro-Q Diamond) detection system to identify the
differentially phosphorylated phosphoproteins between
breast tumors with/without HER-2/neu  overexpression.
The Pro-Q Diamond fluorescence-based system detects
phosphoserine-, phosphothreonine- and phosphotyro-
sine-containing proteins directly in isoelectrofocusing
(IEF) gels, SDS-polyacrylamide gels and two-dimensional
electrophoresis (2-DE) gels, and has been widely used for
phosphoproteomic studies in both cancer cell lines and
clinical tumor samples [27-29]. Our comparative phos-
phoproteomic analyses revealed that Hsp27, one of the
identified phosphoproteins, was highly phosphorylated
in HER-2/neu positive breast tumors. We further investi-
gated the site-specific phosphorylation of Hsp27 at Ser78,
Ser82 and Ser15, with the aim of elucidating the regulatory
role of HER-2/neu-p38MAPK in Hsp27 phosphorylation
and the correlations of their respective pSer profiles with
two adverse criteria, HER-2/neu and lymph node positiv-
ity, associated with tumor progression and poor progno-
sis. To our knowledge, this is the first report to study the
relationship of site-specific phosphorylation of Hsp27
with these two key clinicopathological parameters in
breast cancer.
Results
Identification of phosphoproteins
We found significant differences in the phosphopro-
teomes of HER-2/neu positive and – negative tumors. Fig-
ure 1A shows an example of 2-DE gels stained by both
Pro-Q Diamond and Sypro Ruby. The phosphorylation
levels of protein spots were analyzed based on the ratio of
spot intensity stained by Pro-Q Diamond over that
stained by Sypro Ruby. By using tandem MS/MS peptide
sequencing and database search, four differentially phos-
phorylated proteins were identified as tropomyosin 2(β)
(NP998839), pyridoxine 5'-phosphate oxidase
(NP060599), Hsp27 (AAA62175) and heme-binding pro-
tein 1 (AAP35958). Of these proteins, tropomyosin 2(β)
was highly de-phosphorylated, whereas the other three
proteins, including Hsp27, were highly phosphorylated in
the HER-2/neu positive tumors. The peptide sequence and
Mowse score of Hsp27 are shown in Figure 1B. As Hsp27
is phosphorylated at three serine residues (Ser15, Ser78 and
Ser82) [3], we further analyzed the levels of site-specific
phosphorylation of Hsp27 using the site-specific antibod-
ies on 4 HER-2/neu positive and 4 -negative tumors. As
shown in Figure 2, residue Ser78 of Hsp27 was highly
phosphorylated in HER-2/neu positive tumors (p < 0.05).
There were no significant differences of Hsp27 phosphor-
ylation at Ser15 and Ser82 in the two subtypes of breast
tumor cells.
Ser78 of Hsp27 was highly phosphorylated in HER-2/neu 
positive tumors – tissue lysate array analysis
To further confirm the differential phosphorylation of
Hsp27 between HER-2/neu positive and -negative tumor
cells, the site-specific phosphorylations of Hsp27 of HER-
2/neu positive tumors, -negative tumors and non-tumor
tissues were analyzed using a tissue lysate array. As indi-
cated in Figure 3A, the relative level of pSer82 (pSer82/
Hsp27) was highly increased in both tumor subtypes, as
compared to the non-tumor tissues, but there were no sig-
nificant differences between the HER-2/neu positive and -
negative tumors. For pSer15, no differences were observed
between tumor and non-tumor tissues, nor between the
two subtypes of breast tumors (Figure 3B). The relative
level of pSer78 (pSer78/Hsp27) was, however, significantly
enhanced in HER-2/neu positive tumors (p < 0.05), rela-
tive to those of HER-2/neu  negative tumors and non-
tumor tissues (Figure 3C). These data imply that HER-2/Molecular Cancer 2007, 6:52 http://www.molecular-cancer.com/content/6/1/52
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neu signaling plays a key role in Hsp27 phosphorylation
at Ser78.
Ser78 phosphorylation was significantly stimulated by 
heregulin and inhibited by p38 MAPK inhibitor
We further tested the role of HER-2/neu  signaling in
Hsp27 phosphorylation in the BT474 breast cancer cell
line by treating the serum-starved cell cultures with HRG
α1 for 10 and 30 min. As shown in Figure 4A, HRG α1 sig-
nificantly stimulates phosphorylation of Ser78 and Ser82,
but not Ser15. As phosphorylation of Hsp27 is the down-
stream regulator of p38 MAPK [30], we assessed the effect
of the p38 MAPK pathway on the Hsp27 phosphorylation
profile by inhibiting the p38MAPK pathway with the
inhibitor SB203580. Compared to the untreated control,
the level of pSer78 was significantly reduced by 70% (p <
0.05), whereas that of pSer82 was only inhibited by 30%
(Fig. 4B) in the inhibitor-treated cells. The level of pSer15
was not affected by the inhibition of the p38 MAPK path-
way. Taken together, these data demonstrate that Ser78
phosphorylation is mainly regulated by the HER-2/neu-
p38 MAPK pathway and p38 MAPK is the key kinase for
Hsp27 phosphorylation at Ser78.
Ser78 phosphorylation of Hsp27 was strongly associated 
with HER-2/neu positivity and lymph node metastasis
As Hsp27 phosphorylation was involved in tumor cell
migration and invasion [22], we then investigated the cor-
Identification of phosphoproteins in breast tumors Figure 1
Identification of phosphoproteins in breast tumors. (A) Phosphoprotein staining by Pro-Q Diamond and SYPRO-Ruby 
dyes. Total proteins from both HER-2/neu positive and -negative breast tumors were separated by 2-DE gels and stained with 
fluorescent Pro-Q Diamond for phosphoproteins, followed by SYPRO-Ruby for total proteins. Stained gels were scanned with 
a Typhoon 9600 fluorescence scanner. Images were captured and the relative phosphorylation levels of differentially phospho-
rylated spots were analyzed using the ImageMaster 2D Elite software. Proteins were in-gel digested with trypsin, analyzed using 
4800 MALDI-TOF/TOF™ analyzer and identified by NCBInr database search. Four phosphoproteins were unambiguously 
identified (A: in table, right). (B) Peptide sequences and Mowse scores of Hsp27.Molecular Cancer 2007, 6:52 http://www.molecular-cancer.com/content/6/1/52
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relation of pSer15, pSer78 and pSer82 with HER-2/neu status
and lymph node metastasis using immunohistochemical
staining on TMA sections comprised of 98 breast tumors.
Eighty-nine tumors with available staining information
were examined for probable correlations with the specific
tumor subgroups, as defined by clinical and pathological
variables (e.g., lymph node positivity and HER-2/neu sta-
tus). In all 89 cases, the staining of pSer78, pSer82, pSer15
and Hsp27 were observed in the cytoplasm. We found
that positive anti-pSer78 staining was mostly found in
HER-2/neu positive tumors (p = 0.004) and was strongly
correlated with lymph node positivity (p = 0.026) (Table
1). Figure 5 shows an example of negative, moderate and
strong staining by the anti-pSer78  antibody. We also
observed that whilst the extent of Hsp27 staining showed
a moderate association with HER-2/neu status (p = 0.041),
no parallel strong correlation with lymph node status (p =
0.558) was found. There were also no significant correla-
tions of pSer15 and pSer82 levels with either of these clin-
icopathological parameters.
Discussion
The HER-2/neu gene encodes c-ErbB2, a member of the
ErbB family of transmembrane tyrosine kinase receptors.
Heterodimerization with ErbB3 and ErbB4 and subse-
quent autophosphorylation of HER-2/neu  activates the
downstream MAPK-Erk1/2 and PI3K-Akt pathways which
Western blotting of Hsp27, pSer15, pSer78 and pSer82 Figure 2
Western blotting of Hsp27, pSer15, pSer78 and pSer82. 
Twenty μg proteins from each of 4 HER-2/neu positive and 4 
-negative tumour samples were separated by 10% SDS-PAGE 
and transferred onto PVDF membranes. After blocking, the 
membranes were incubated with the respective primary anti-
bodies (anti-Hsp27, anti-pSer15, anti-pSer78 and anti-pSer82), 
followed by hybridization to HRP-conjugated secondary anti-
body. The chemiluminescent signals emitted were captured 
with the MULTI-GENIUS Bio-Imaging System and signal 
intensities were analyzed using the GeneTools software (Syn-
gene). The relative phosphorylation levels of pSer15, pSer78 
and pSer82 presented (histograms, right) are the respective 
ratios of signal intensity probed with phosphorylation site-
specific antibody to signal intensity probed with anti-Hsp27, 
for each of the three pSer residues. Data with ± SD (stand-
ard deviation) are expressed as the average of triplicate 
experiments. *p < 0.05 (Student t-test).
Tissue lysate array analyses of Hsp27, pSer15, pSer78 and  pSer82 Figure 3
Tissue lysate array analyses of Hsp27, pSer15, pSer78 
and pSer82. Equal amounts of total proteins from normal 
tissues (n = 10), HER-2/neu positive (n = 10) and HER-2/neu 
negative (n = 10) breast tumor tissues were manually arrayed 
on the PVDF membrane in duplicates. Arrays were probed 
with the respective antibodies and the chemiluminescent sig-
nals generated were detected as described in Figure 2. The 
relative phosphorylation levels (pSer/Hsp27) of Hsp27 at 
Ser82 (A), Ser15 (B), and Ser78 (C) of each tissue subtype were 
expressed as the ratio of spot intensity probed with phos-
phorylation site-specific antibody to the spot intensity 
probed with anti-Hsp27. The overall average level of pSer/
Hsp27 with the standard deviation (± SD), as presented (his-
tograms with error bars) was calculated from 10 cases of 
each tissue subtype (normal, HER-2/neu negative and HER-2/
neu positive tumor tissues). * Significant differences of three 
groups (normal, HER-2/neu positive and -negative tumors) 
were calculated using ANOVA. *p < 0.05.Molecular Cancer 2007, 6:52 http://www.molecular-cancer.com/content/6/1/52
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are central to cell proliferation and survival. The results of
our study lend further credence to the view that HER-2/
neu-mediated phosphorylations of proteins play a key
contributory role to poor clinical outcome and resistance
to chemo- and hormonal therapies. In this study, we
investigated the differential phosphoproteomes by com-
paring the PRO-Q Diamond stained-phosphoprotein pro-
files between the LCM-procured HER-2/neu positive and -
negative tumor cells. Several differentially affected phos-
phoproteins, including Hsp27, pyridoxine 5'-phosphate
oxidase, heme-binding protein 1 and tropomyocin 2(β)
were identified. As inhibition of Hsp27 phosphorylation
reportedly blocked tumor cell migration and invasion
[22], we further extended our work to investigate the asso-
ciation(s) of Hsp27 phosphorylation at three sites (Ser15,
Ser78 and Ser82) with HER-2/neu status and lymph node
metastasis in breast cancer. To the best of our knowledge,
this is the first report showing the strong relationship of
pSer78, but not pSer82 and pSer15, of Hsp27 with HER-2/
neu status and lymph node positivity in breast cancer.
Hsp27 phosphorylation has been previously reported to
be regulated by several pathways, including those of
MAPKAPK2/3, PKC/D and Stat3 [14-19]. In this study, to
test whether the phosphorylation of Hsp27 at different
serine sites was affected by HER-2/neu  signaling, we
treated the BT474 cell line with HRG α1 and with
SB203580. Not surprisingly, our data demonstrated that
HRGα1 treatment enhanced the phosphorylation of
Hsp27 at Ser78 and Ser82, though not at Ser15. Further-
more, the p38MAPK inhibitor, SB203580, significantly
reduced the level of pSer78 (p < 0.05), but similar effect on
the level of pSer82 was not seen, (Figure 4). These data
demonstrated that phosphorylation of the Ser78 residue of
Hsp27 was mainly regulated by the HER-2/neu-p38 MAPK
pathway. Notably, Song et al. [19] had found that phos-
phorylation of the Ser78 residue was mainly induced by
Stat3 in MCF-10A and MDA-MB-453 breast cells, further
corroborating the role of pSer78 in the aberrant Stat3 sign-
aling-induced cell malignancies. When the MCF-7 cells
were treated with the microtubule interfering agent vinc-
ristine, phosphorylation of Hsp27 at Ser78 was markedly
induced, implying its role in resisting the microtubule
dynamic interference by anti-tumoral drugs and enhanc-
ing cell survival [31]. As phosphorylation of Hsp27 regu-
lated cell invasion and migration [22,30], our study
suggests that the enhanced HER-2/neu-p38MAPK-
pSer78Hsp27 signal could be one of the main regulatory
mechanisms in the HER-2/neu-driven cell invasion and
metastasis.
In studies with resected tumor specimens, it had been
found that Hsp27 was highly phosphorylated at Ser82 in
renal cell carcinoma [23], whereas in hepatocellular carci-
noma, its phosphorylations at three Ser residues were
inversely correlated with tumor size, microvascular inva-
sion and tumor stage [24]. In our study, we observed that
Ser78 of Hsp27 was highly phosphorylated in HER-2/neu
positive breast tumors by both Western blot and tumor
lysate array analyses (Figures 2 &3). We also showed that
immunohistochemical staining intensity strongly corre-
lated to lymph node positivity in the breast tumors tested
(p = 0.026) (Table 1). These observations indicate that
enhanced phosphorylation of Ser78 could be an important
effector in driving or facilitating in vivo tumor cell inva-
sion and metastasis. However, larger-scale investigations
involving more clinical specimens and more extensive
clinical evaluations are needed to clarify the exact role of
pSer78 of Hsp27 in breast cancer development and pro-
Effect of heregulin α1 (HRG α1) and p38 MAPK inhibitor (SB  203580) on Hsp27 phosphorylation Figure 4
Effect of heregulin α1 (HRG α1) and p38 MAPK inhib-
itor (SB 203580) on Hsp27 phosphorylation. Cultures 
of cells from the BT474 breast cancer cell line were treated 
with HRG α1 for 10 and 30 min (A) or SB 203580 for 10 
hours (B) and total cell lysates were extracted using M-PER 
reagent (Pierce). Equal amounts of proteins (20 μg) were 
separated by SDS-PAGE and transferred onto PVDF mem-
brane. The membranes were blocked for 1 hour, followed by 
being probed with the respective primary antibodies (anti-
Hsp27, anti-pSer15, anti-pSer78 and anti-pSer82), and HRP-
conjugated secondary antibody. The signals were captured 
and their intensities were detected as described in Figure 2. 
The phosphorylation levels of pSer15, pSer78 and pSer82 were 
expressed as the ratios of intensity probed with phosphor-
ylation site-specific antibody to the intensity probed with 
anti-Hsp27. Data with ± SD represents the average of tripli-
cate experiments. C: control; SB: inhibitor SB203580. For the 
control of HRG-treated cells, untreated cells were cultured 
for 10 and 30 min and equal amounts of cellular proteins 
from both time intervals were mixed and used as control. 
For the control of inhibitor-treated cells, cells were treated 
with DMSO for 10 hours and cellular proteins were used as 
the control. *p < 0.05 (student t-test)Molecular Cancer 2007, 6:52 http://www.molecular-cancer.com/content/6/1/52
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gression. From the clinicopathologic point of view, the
pSer78 level could serve as a potential biomarker for pre-
dicting the extent of malignancy and metastasis in breast
cancer.
Conclusion
Our phosphoproteomics study identified the enhanced
phosphorylation of Hsp27 in HER-2/neu positive breast
tumors. The pSer78 level, in particular, was mainly regu-
lated by the HER-2/neu-p38MAPK pathway, and strongly
correlated with HER-2/neu and lymph node positivity in
breast tumors.
Methods
Clinical specimens
The HER-2/neu status of breast tumors was evaluated by
fluorescence in situ hybridization (FISH) using the Path-
Vysion kit (Vysis, Downers Grove, IL) and immunohisto-
chemistry (IHC) using the HercepTest Kit (Dako,
Glostrup, Denmark), according to the manufacturers'
instructions. A cutoff value of ≥ 2:1 signal ratio (HER-2
locus: CEP-17 centromere locus) was defined as HER-2/
neu gene amplification for FISH, and moderate (+2) to
strong (+3) staining of plasma membrane was scored as
positive for IHC [32]. For this study, 28 frozen breast
tumor tissues (14 HER-2/neu positive and 14 HER-2/neu
negative as determined by FISH and 28 adjacent non-
tumor tissues (as controls) were obtained from the Tissue
Repository of the Singapore National University Hospital,
with informed patient consent. Usage of these tissues
complied with the regulations set by our Institutional
Review Board (IRB) for research purposes. All the tumors
were diagnosed as invasive carcinoma during the diagnos-
tic workup by certified pathologists. Four of the HER-2/
neu-positive tumors and four of the HER-2/neu-negative
tumors were used for phosphoproteomic analyses and the
rest were used for tissue lysate array analyses.
Microdissection and protein sample preparation
Tumor cells from 4 HER-2/neu positive and 4 HER-2/neu
negative tumor tissues were dissected using the PixCell II
LCM System (Arcturus Engineering, Mountain View, CA),
as previously described [6,33]. Cells were immediately
lysed in the lysis buffer and the protein concentration of
each sample was assayed using the PlusOne 2-D Quanti-
tation Kit (GE Healthcare, San Francisco, CA). To get
enough proteins in the samples for 2-DE separations,
equal amounts of proteins from each of the 4 HER-2/neu
positive cases and each of the 4 HER-2/neu negative cases
were pooled, respectively. The proteins were separated
using immobiline IPG DryStrips (180 mm, pH 4–7) and
10% homogeneous SDS-PAGE gels, as described previ-
ously [33].
Phosphoprotein staining and image analysis
Phosphoproteins were stained using the fluorescent Pro-
Q Diamond dye, according to the protocol provided by
the manufacturer. Briefly, 2-DE gels were fixed overnight
in solution containing 45% methanol and 5% acetic acid,
followed by washing with deionized water. Gels were
incubated in Pro-Q Diamond stain for 2 hours, and
destained by washing in 20% acetonitrile in 50 mM
sodium acetate (pH 4.0) for 1 hour. After the gels were
rehydrated in deionized water for 40 min, the phospho-
protein spots were visualized using the Typhoon 9600 flu-
orescence scanner (GE Healthcare), with excitation at 532
nm and image capture with the 580 nm long-pass emis-
sion filter. Following the phosphoprotein image acquisi-
tion, the gels were re-stained for total proteins with
SYPRO Ruby and images were acquired again by the same
Table 1: Association of Hsp27 phosphorylation with HER-2/neu status and lymph node positivity
HER-2/neu statusb Lymph node
Intensitya Positive (n = 21) Negative (n = 68) p Positive (n = 36) Negative (n = 53) p
pSer78
N23 0 82 4
P 19 38 0.004 28 29 0.026
pSer82
N 8 40 20 28
P 13 28 0.096 16 25 0.800
pSer15
N1 55 3 2 64 2
P 6 15 0.539 10 11 0.444
Hsp27
N 3 26 13 16
P 18 42 0.041 23 37 0.558
a staining level was defined as negative for negative/weak staining and positive for moderate and strong staining. P: positive; N: negative. b HER-2/neu 
status was described based on FISH: the cutoff value for positive is ≥ 2:1 (HER-2 locus: CEP-17). p value was calculated from the chi-square test. 
Significance was set at p < 0.05.Molecular Cancer 2007, 6:52 http://www.molecular-cancer.com/content/6/1/52
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scanner, with excitation at 473 nm and image capture
using the 580 nm long-pass emission filter. Computer-
generated differential display maps (pseudocolor images)
of protein phosphorylation and protein expression pat-
terns were converted into intensity signals and analyzed
using the ImageMaster 2D Elite software (GE Healthcare).
Spots with at least 1.5-fold changes in the ratio of phos-
phorylated protein/total protein intensities were excised
and digested with sequencing-grade trypsin (Promega,
Madison, WI). The trypsinised proteins were analyzed
using a 4800 MALDI-TOF/TOF™ analyzer (Applied Bio-
systems, Foster City, CA) and identified by searching the
NCBInr database using the Mascot search program
(Matrix Science, London, UK), as previously described [6].
Cell culture and treatment
The human BT474 breast cancer cell line was obtained
from American Type Culture Collection, and maintained
in modified Dulbecco's medium (HybriCare) supple-
mented with 10% fetal bovine serum (FBS) at 37°C in a
humidified atmosphere of 5% CO2 in an incubator. Prior
to HRG α1 (Neomarkers, Fremont, CA) or p38MAPK
inhibitor, SB203580 (Calbiochem®, Darmstadt, Ger-
many) treatment, the BT474 cells (at ~80% confluence)
were serum-starved for 20 hours in medium lacking FBS.
For HRG α1 treatment, the starved cells were then exposed
to FBS-supplemented medium with 0.3 nM of HRG α1 for
10 min and 30 min. Cells without HRG α1 treatment were
cultured for 10 and 30 min, respectively, and equal
amounts of total proteins from untreated cells at both
time intervals were mixed and used as controls for West-
ern blotting. For the inhibitor treatment, inhibitor
SB203580 (5 mg) was dissolved in DMSO to a stock con-
centration of 40 mM. The starved cells were exposed to
FBS-supplemented medium with 40μM of the SB203580
(1:1000 dilution) for 10 hours. The starved cells treated
for 10 hrs with equal volume of DMSO were used as con-
trol. Total cell lysates were extracted using M-PER reagent
Representative immunohistochemical staining of pSer78 on breast tumor tissue microarray (TMA) Figure 5
Representative immunohistochemical staining of pSer78 on breast tumor tissue microarray (TMA). TMA sec-
tions were deparaffinized in xylene and rehydrated in graded alcohols and processed as described previously [6]. After antigen 
retrieval and removal of endogenous peroxidases, the sections were incubated for 1 hour with anti-pSer78 antibody and the 
hybridized complex stained with labeled dextran polymer conjugated with peroxidase and DAB+-substrate chromagen solu-
tion, counterstained with Mayer's hematoxylin and mounted for scoring. The extent of staining was scored as negative, weak, 
moderate and strong, based on the stain intensity. (A-C): Hematoxylin-Eosin (H&E) staining of tumor sample; (D) Negative 
staining; (E): Moderate staining; (F): Strong staining. Original magnification × 400.Molecular Cancer 2007, 6:52 http://www.molecular-cancer.com/content/6/1/52
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(Pierce, Rockford, IL) and their protein concentrations
were measured by the Coommassie Plus™ Protein Assay
Kit (Pierce).
Immunoblotting
Cellular proteins (20 μg) were resolved by 10% SDS-
PAGE gels and transferred onto PDVF membranes (GE
Healthcare). After blocking with 5% bovine serum albu-
min in Tris-buffered saline containing 0.1% Tween-20,
the membranes were incubated overnight at 4°C with the
primary antibodies listed in Table 2. The horseradish per-
oxidase-conjugated goat anti-mouse IgG (1:10,000,
Upstate Biotechnology Inc., Lake Placid, NY) or goat anti-
rabbit IgG (1:10,000, ZyMED Laboratories Inc., San Fran-
cisco, CA) secondary antibody was then applied and the
chemiluminescent signals generated using the SuperSig-
nal® West Pico Chemiluminescent Substrate (Pierce) were
captured with the MULTI GENIUS Bio Imaging System
(Syngene, Frederick, MD) and the signal intensities ana-
lyzed using the GeneTools software (Syngene).
Tissue lysate array analysis was carried out as described
[33]. Briefly, aliquots of 0.5 μl of each sample were man-
ually spotted onto the PDVF membrane in duplicates. A
total of 30 samples – 10 of HER-2/neu-positive tumors, 10
of HER-2/neu-negative tumors and 10 of non-tumor tis-
sue samples, were arrayed. Treatment of the arrayed mem-
branes and detection of signals with anti-Hsp27 and its
phosphorylation site-specific antibodies followed the
same procedures as for the immunoblot described above.
The relative phosphorylation levels of pSer15, pSer78 and
pSer82  were individually expressed as pSer/Hsp27: the
ratio of spot signal intensity observed when probed with
the respective phosphorylation site-specific antibodies to
the spot intensity observed when probed with anti-Hsp27
antibody.
Tissue microarray and immunohistochemistry
Two tissue microarrays (TMAs) containing 97 breast
tumors and their corresponding matched, non-tumor
controls were constructed previously [34]. To analyze the
expression of Hsp27 and its site-specific pSer levels in
breast tumors, TMA sections of 4-μm thickness were cut
from the TMA block and immunostaining was carried out
using the DAKO Envision+ system (Dako, Glostrup, Den-
mark), as described previously [32]. Briefly, sections were
dewaxed in xylene and rehydrated in graded alcohols
(100%, 95%, and 75%). Antigen unmasking was done
using the DAKO® Target Retrieval Solution in a microwave
oven. Endogenous peroxidases were blocked for 1 hour
using the supplied Peroxidase block. Sections were incu-
bated for 1 hour with each of the 4 antibodies: anti-Hsp27
(1: 500), anti-pSer15 (1:250), anti-pSer78 (1:250) and anti-
pSer82 (1:250), followed by detection with labeled dex-
tran polymer conjugated with peroxidase and DAB+-sub-
strate chromagen solution. Three sections were stained
with each of the four antibodies. The staining intensities
of individual tumor cores on each section were independ-
ently scored under a light microscope by a pathologist and
the principal researcher (ZD). Cases with discrepant
scores were rescored by the same or additional scorers to
obtain a consensus score. Staining levels were scored as
negative, weak, moderate and strong, based on the stain-
ing intensity in the tumor cells. Cases with negative and
weak staining intensities were considered as negative;
whereas cases with moderate and strong staining intensi-
ties were considered as positive. For negative controls, we
omitted addition of the primary antibody in the staining
protocol.
Statistical analysis
One-way analysis of variance (ANOVA) was used to com-
pare the significance of differences of Hsp27 phosphoryla-
tion levels among the three groups of samples: HER-2/neu
positive tumors, -negative tumors and non-tumor sam-
ples. The correlation of the expression of pSer15, pSer78
and pSer82 with the clinicopathologic variables (HER-2/
neu and lymph node) was analyzed with the chi-square
test. Two-sided p < 0.05 was considered as of significance.
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